Patients waiting for a small surgical implant that treats their sleep apnea by stimulating the hypoglossal nerve are now likely to wait longer in 2026, after the company that makes the device cut its full-year revenue outlook by more than $100 million. Inspire Medical Systems reported first-quarter 2026 revenue of $204.6 million (up 1.6% year-on-year) on 4 May 2026 and revised full-year 2026 guidance down to $825-875 million from the prior $950 million-$1 billion range issued in February. The Inspire procedure got caught in a CMS prior-authorization programme called WISeR and a CPT code transition that have together slowed insurance approvals and pushed procedures into later quarters. Bank of America analyst Travis Steed downgraded the stock from Neutral to Underperform on the same week.

The cut and what’s in it

Inspire entered 2026 expecting to grow revenue 4-10% to $950 million-$1 billion. After Q1, the company now expects revenue of $825-875 million for the year, a projected decline of 4-10% compared to 2025. The cut is roughly $125 million at the midpoint. Inspire attributed approximately $20 million of Q1 impact to CMS WISeR and CPT code transition uncertainty, and now expects the total impact for the full year to be $120-150 million, with the most dramatic impact concentrated in Q2.

Q1 revenue itself was $204.6 million, up 1.6% year-on-year. Growth has effectively stalled. The Q1 figure beat consensus estimates marginally but the forward outlook drove the stock lower on the earnings release.

What WISeR is doing to Inspire’s revenue

WISeR (Wasteful and Inappropriate Service Reduction) is the CMS prior-authorization programme that took effect on 1 January 2026, requiring physicians to obtain CMS approval before performing certain procedures. The programme covers a defined services list, and the Inspire hypoglossal nerve stimulation procedure for moderate-to-severe obstructive sleep apnea is on that list. NeuroPace’s RNS System for refractory epilepsy is not. Inside BCI covered the bifurcation on 8 May and extended the analysis on 18 May with NeuroPace’s Q1 print, where NeuroPace posted +20% revenue growth and raised guidance in the same window Inspire was cutting.

The Q1 mechanics for Inspire are concrete. WISeR slowed prior authorization submissions, which delayed procedure scheduling, which pushed revenue from Q1 into Q2 or later. The CPT code transition (Inspire is moving its primary procedure code to 64582 with a -52 modifier) created additional billing uncertainty, with physician reimbursement rates still settling. The combination froze the commercial pipeline.

The cut is also not purely about WISeR. Inspire’s Q1 commentary attributed the headwinds to four stacked factors: WISeR coding uncertainty, GLP-1 medication competition (Ozempic and Wegovy reduce some patients’ weight-related sleep apnea symptoms), salesforce disruption, and increased competition from devices and alternative therapies. WISeR is the largest of the four but not the only one.

The BofA call

Bank of America analyst Travis Steed downgraded Inspire Medical from Neutral to Underperform on the same week as the guidance cut, citing the coding uncertainty as the primary driver. Steed wrote that he does not see a path for the stock to work until there is clarity on coding, and that he sees higher risk to estimates without code clarity. The downgrade is a market-level confirmation of the structural concern, not just a reaction to one quarter.

The Underperform rating is meaningful because BofA was Neutral going into the earnings, not bullish. Steed’s call is that the WISeR overhang is not a transient first-half issue but a structural problem that will need formal coding resolution before Inspire’s revenue trajectory can stabilise.

How this confirms the 8 May bifurcation thesis

Inside BCI’s 8 May piece argued that the CMS WISeR rule was creating a structural bifurcation in the neuromodulation market, with Inspire on the losing side and NeuroPace on the winning side based on whether each device’s procedure code was on the WISeR services list. Three weeks later, the market is pricing exactly that split. NeuroPace raised guidance and posted +20% growth in the same window that Inspire cut by $125 million and got a BofA downgrade.

The pattern matters beyond these two companies. WISeR is a payer-policy lever that will continue to differentiate neuromodulation devices through 2026 and beyond. Companies whose procedure codes are on the WISeR list face a structural revenue headwind that cannot be solved by clinical execution alone. Companies off the list scale into the available payer environment.

What to watch

The first signal is the CMS coding decision on Inspire V (the next-generation device) and the resolution of the CPT 64582 reimbursement rate. Inspire has stated that the most dramatic WISeR impact will be in Q2, with stabilisation expected in the second half if coding clarity arrives. The second signal is the Q2 print itself, which will tell the market whether the company has reached the bottom of the WISeR drag or whether the impact continues to widen. The third signal is whether any of Inspire’s adjacent neuromodulation peers (Boston Scientific, Medtronic, NeuroPace) take share of the OSA market while Inspire’s commercial pipeline is constrained. Boston Scientific’s January 2026 acquisition of Axonics opens the door to a sacral-neuromodulation entry into adjacent indications; whether Boston Scientific or another incumbent moves on OSA explicitly is now the more interesting strategic question.

Sources

• Inspire Medical slashes 2026 guidance amid reimbursement uncertainty (MassDevice, May 2026)
• Inspire Medical Q1 Earnings Beat Estimates, 2026 View Cut, Stock Down (TradingView / Zacks)
• BofA analysts downgrade Inspire Medical on reimbursement coding concerns (MassDevice)
• Inspire Medical Systems Q1 Earnings Call Highlights (Yahoo Finance)
• Inspire Medical Systems signals 2026 revenue outlook of $950M-$1B (Seeking Alpha, February 2026)
• Full Transcript: Inspire Medical Systems Q1 2026 Earnings Call (Benzinga)